165 related articles for article (PubMed ID: 37171617)
21. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.
Garner JM; Ellison DW; Finkelstein D; Ganguly D; Du Z; Sims M; Yang CH; Interiano RB; Davidoff AM; Pfeffer LM
PLoS One; 2015; 10(5):e0125838. PubMed ID: 25955030
[TBL] [Abstract][Full Text] [Related]
22. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.
Jiang P; Mukthavaram R; Chao Y; Bharati IS; Fogal V; Pastorino S; Cong X; Nomura N; Gallagher M; Abbasi T; Vali S; Pingle SC; Makale M; Kesari S
J Transl Med; 2014 Jan; 12():13. PubMed ID: 24433351
[TBL] [Abstract][Full Text] [Related]
23. Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models.
Stockslager MA; Malinowski S; Touat M; Yoon JC; Geduldig J; Mirza M; Kim AS; Wen PY; Chow KH; Ligon KL; Manalis SR
Cell Rep; 2021 Oct; 37(1):109788. PubMed ID: 34610309
[TBL] [Abstract][Full Text] [Related]
24. Secondary gliosarcoma: the clinicopathological features and the development of a patient-derived xenograft model of gliosarcoma.
Kiang KM; Chan AA; Leung GK
BMC Cancer; 2021 Mar; 21(1):265. PubMed ID: 33706745
[TBL] [Abstract][Full Text] [Related]
25. Dexamethasone-mediated oncogenicity in vitro and in an animal model of glioblastoma.
Luedi MM; Singh SK; Mosley JC; Hassan ISA; Hatami M; Gumin J; Andereggen L; Sulman EP; Lang FF; Stueber F; Fuller GN; Colen RR; Zinn PO
J Neurosurg; 2018 Dec; 129(6):1446-1455. PubMed ID: 29328002
[TBL] [Abstract][Full Text] [Related]
26. Translational validation of personalized treatment strategy based on genetic characteristics of glioblastoma.
Oh YT; Cho HJ; Kim J; Lee JH; Rho K; Seo YJ; Choi YS; Jung HJ; Song HS; Kong DS; Seol HJ; Lee JI; Yoon Y; Kim S; Nam DH; Joo KM
PLoS One; 2014; 9(8):e103327. PubMed ID: 25084005
[TBL] [Abstract][Full Text] [Related]
27. Antitumor effects of minodronate, a third-generation nitrogen-containing bisphosphonate, in synergy with γδT cells in human glioblastoma in vitro and in vivo.
Nakazawa T; Nakamura M; Matsuda R; Nishimura F; Park YS; Motoyama Y; Hironaka Y; Nakagawa I; Yokota H; Yamada S; Tamura K; Takeshima Y; Omoto K; Tanaka Y; Ouji Y; Yoshikawa M; Tsujimura T; Nakase H
J Neurooncol; 2016 Sep; 129(2):231-41. PubMed ID: 27393349
[TBL] [Abstract][Full Text] [Related]
28. Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.
Verreault M; Schmitt C; Goldwirt L; Pelton K; Haidar S; Levasseur C; Guehennec J; Knoff D; Labussière M; Marie Y; Ligon AH; Mokhtari K; Hoang-Xuan K; Sanson M; Alexander BM; Wen PY; Delattre JY; Ligon KL; Idbaih A
Clin Cancer Res; 2016 Mar; 22(5):1185-96. PubMed ID: 26482041
[TBL] [Abstract][Full Text] [Related]
29. Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action.
Punganuru SR; Artula V; Zhao W; Rajaei M; Deokar H; Zhang R; Buolamwini JK; Srivenugopal KS; Wang W
Cells; 2020 Jul; 9(7):. PubMed ID: 32630235
[TBL] [Abstract][Full Text] [Related]
30. Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy.
Kanemaru Y; Natsumeda M; Okada M; Saito R; Kobayashi D; Eda T; Watanabe J; Saito S; Tsukamoto Y; Oishi M; Saito H; Nagahashi M; Sasaki T; Hashizume R; Aoyama H; Wakai T; Kakita A; Fujii Y
Acta Neuropathol Commun; 2019 Jul; 7(1):119. PubMed ID: 31345255
[TBL] [Abstract][Full Text] [Related]
31. Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
Zhang J; Xue W; Xu K; Yi L; Guo Y; Xie T; Tong H; Zhou B; Wang S; Li Q; Liu H; Chen X; Fang J; Zhang W
Theranostics; 2020; 10(16):7245-7259. PubMed ID: 32641990
[No Abstract] [Full Text] [Related]
32. Functional Precision Oncology: The Next Frontier to Improve Glioblastoma Outcome?
Panovska D; De Smet F
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955765
[TBL] [Abstract][Full Text] [Related]
33. Tannic acid elicits selective antitumoral activity in vitro and inhibits cancer cell growth in a preclinical model of glioblastoma multiforme.
Bona NP; Pedra NS; Azambuja JH; Soares MSP; Spohr L; Gelsleichter NE; de M Meine B; Sekine FG; Mendonça LT; de Oliveira FH; Braganhol E; Spanevello RM; da Silveira EF; Stefanello FM
Metab Brain Dis; 2020 Feb; 35(2):283-293. PubMed ID: 31773434
[TBL] [Abstract][Full Text] [Related]
34. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.
Onken J; Torka R; Korsing S; Radke J; Krementeskaia I; Nieminen M; Bai X; Ullrich A; Heppner F; Vajkoczy P
Oncotarget; 2016 Mar; 7(9):9876-89. PubMed ID: 26848524
[TBL] [Abstract][Full Text] [Related]
35. Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity.
Meyer M; Reimand J; Lan X; Head R; Zhu X; Kushida M; Bayani J; Pressey JC; Lionel AC; Clarke ID; Cusimano M; Squire JA; Scherer SW; Bernstein M; Woodin MA; Bader GD; Dirks PB
Proc Natl Acad Sci U S A; 2015 Jan; 112(3):851-6. PubMed ID: 25561528
[TBL] [Abstract][Full Text] [Related]
36. Anticancer activity of osmium(VI) nitrido complexes in patient-derived glioblastoma initiating cells and in vivo mouse models.
Berger G; Grauwet K; Zhang H; Hussey AM; Nowicki MO; Wang DI; Chiocca EA; Lawler SE; Lippard SJ
Cancer Lett; 2018 Mar; 416():138-148. PubMed ID: 29246647
[TBL] [Abstract][Full Text] [Related]
37. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
[TBL] [Abstract][Full Text] [Related]
38. Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models.
Teng J; da Hora CC; Kantar RS; Nakano I; Wakimoto H; Batchelor TT; Chiocca EA; Badr CE; Tannous BA
Neuro Oncol; 2017 Jun; 19(6):820-832. PubMed ID: 28062830
[TBL] [Abstract][Full Text] [Related]
39. Identification and characterization of a small-molecule inhibitor of Wnt signaling in glioblastoma cells.
De Robertis A; Valensin S; Rossi M; Tunici P; Verani M; De Rosa A; Giordano C; Varrone M; Nencini A; Pratelli C; Benicchi T; Bakker A; Hill J; Sangthongpitag K; Pendharkar V; Liu B; Ng FM; Then SW; Jing Tai S; Cheong SM; He X; Caricasole A; Salerno M
Mol Cancer Ther; 2013 Jul; 12(7):1180-9. PubMed ID: 23619303
[TBL] [Abstract][Full Text] [Related]
40. Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma.
Narayan RS; Gasol A; Slangen PLG; Cornelissen FMG; Lagerweij T; Veldman HYYE; Dik R; van den Berg J; Slotman BJ; Würdinger T; Haas-Kogan DA; Stalpers LJA; Baumert BG; Westerman BA; Theys J; Sminia P
Mol Cancer Ther; 2018 Feb; 17(2):347-354. PubMed ID: 28958992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
